Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $732.73 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.95 billion
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -11.49%
Earnings Yield N/A
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

If you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 now

You don't have to have 100% winners in your portfolio. Just check out this star, which could have carried the…

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Share Fallers

Why Botanix, Nick Scali, Resolute, and Sayona Mining shares are dropping

These ASX shares are under pressure on Tuesday. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

Man slipping over on banana skin
Healthcare Shares

Here's why the Botanix (ASX:BOT) share price is slipping today

Botanix was busy over the fourth quarter, but its accomplishments aren't being well received by the market.

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Blazing it? How the top ASX cannabis shares performed in FY21

How did ASX cannabis shares fare in FY21?

Read more »

rising asx share price represented by happy woman dancing excitedly
Share Gainers

The Botanix (ASX:BOT) share price jumped 20% today

This cannabis focused biotech company was on form on Friday...

Read more »

A man holds his hands out and shrugs.
Share Market News

What's with the Botanix (ASX:BOT) share price today?

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is relatively stagnant on the company's half-year results and management expansion.

Read more »

falling asx share price represented by business man giving thumbs down gesture
Share Market News

Botanix (ASX:BOT) share price falls despite big tax refund

The Botanix Pharmaceuticals (ASX: BOT) share price is edging higher this morning. We look at the company's latest release.

Read more »

BOT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.

BOT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
19 May 2025 $0.38 $-0.01 -2.60% 6,913,264 $0.39 $0.39 $0.37
16 May 2025 $0.39 $0.01 2.63% 6,167,950 $0.39 $0.40 $0.38
15 May 2025 $0.38 $-0.02 -5.00% 4,876,364 $0.40 $0.41 $0.38
14 May 2025 $0.40 $0.01 2.53% 8,684,965 $0.40 $0.41 $0.39
13 May 2025 $0.40 $-0.01 -2.47% 17,962,682 $0.42 $0.44 $0.40
12 May 2025 $0.41 $-0.06 -12.90% 39,150,601 $0.44 $0.44 $0.38
09 May 2025 $0.47 $0.00 0.00% 2,843,339 $0.47 $0.47 $0.45
08 May 2025 $0.47 $0.02 4.44% 5,793,863 $0.45 $0.47 $0.45
07 May 2025 $0.45 $0.01 2.27% 6,802,864 $0.45 $0.45 $0.42
06 May 2025 $0.44 $-0.01 -2.22% 3,382,107 $0.45 $0.46 $0.44
05 May 2025 $0.45 $-0.01 -2.20% 4,320,015 $0.46 $0.48 $0.45
02 May 2025 $0.46 $0.01 2.25% 10,253,453 $0.45 $0.47 $0.44
01 May 2025 $0.45 $-0.01 -2.22% 9,919,533 $0.46 $0.46 $0.42
30 Apr 2025 $0.45 $0.01 2.27% 10,890,639 $0.45 $0.46 $0.43
29 Apr 2025 $0.44 $0.04 9.88% 7,963,814 $0.41 $0.45 $0.41
28 Apr 2025 $0.41 $-0.02 -4.76% 5,983,154 $0.43 $0.44 $0.41
24 Apr 2025 $0.42 $-0.01 -2.35% 10,701,984 $0.42 $0.44 $0.40
23 Apr 2025 $0.43 $0.03 7.59% 6,938,022 $0.41 $0.43 $0.41

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Mar 2025 Daniel Sharp Exercise 4,000,000 $1,740,000
Exercise of options.
20 Mar 2025 Daniel Sharp Issued 3,111,145 $1,353,348
Exercise of options.
27 Feb 2025 Stewart Washer Issued 3,990,099 $1,815,495
Exercise of options.
27 Feb 2025 Stewart Washer Exercise 5,000,000 $2,275,000
Exercise of options.
15 Jan 2025 Vince Ippolito Sell 3,800,000 $1,672,000
On-market trade.
08 Jan 2025 Vince Ippolito Buy 8,000,000 $3,680,000
Conversion of securities.
08 Jan 2025 Vince Ippolito Exercise 8,000,000 $3,680,000
Conversion of securities. 16,000,000 - Performance Rights
07 Jan 2025 Vince Ippolito Transfer 10,801,644 $4,158,632
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market
07 Jan 2025 Vince Ippolito Transfer 10,801,644 $4,158,632
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market
02 Dec 2024 Matthew (Matt) Callahan Issued 3,000,000 $1,050,000
Issue of securities. 3,000,000 Performance Right
02 Dec 2024 Stewart Washer Issued 3,000,000 $1,050,000
Issue of securities. 3,333,333 Rights
02 Dec 2024 H. William Bosch Issued 3,000,000 $1,050,000
Issue of securities. 3,000,000 Performance Rights
02 Dec 2024 Vince Ippolito Issued 24,000,000 $8,400,000
Issue of securities. 24,000,000 Performance Rights
02 Dec 2024 Daniel Sharp Issued 3,000,000 $1,050,000
Issue of securities. 3,333,333 Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Matthew (Matt) Callahan Executive Director Feb 2020
Mr Callahan is a life sciences executive based in Philadelphia and a founder of Botanix. He has been the founding CEO or Executive Director of a number of ASX listed and private pharmaceutical and health tech companies, including iCeutica Inc, Churchill Pharmaceuticals LLC, Dimerix Biosciences Ltd, Orthocell Ltd, Respirion Pharmaceuticals Pty Ltd, Rumin8 Pty Ltd and Emyria Ltd. Mr Callahan has led the development and commercialization of several products that have received FDA and other global regulatory approvals, he has more than 25 years of industry, IP and legal experience.
Dr Stewart James Washer Non-Executive Director Feb 2019
Dr Washer has CEO and board experience in medical biotech and device companies. Dr Washer chaired Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors in 2010. He has been a Senator with Murdoch University and a director of AusBiotech Ltd.
Dr H. William Bosch Non-Executive Director Jul 2023
Dr Bosch is a pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA-approved prescription drug products. Earlier in his career Dr Bosch was a creator in the application of nanotechnology to pharmaceutical product development. He served as a co-founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
Mr Ippolito has more than 35 years of experience in the pharmaceuticals industry, including over 20 years of experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company.
Mr Daniel Sharp Non-Executive Director Mar 2022
Mr Sharp is an investment banker with more than 30 years of experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has experience in sourcing and servicing both of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity for 8 years and previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
Ms Susan Patricia Park Company Secretary Apr 2023
-
Dr Howie McKibbon Chief Executive Officer Aug 2023
-
Howie McKibbon Chief Executive Officer
-
Graeme Morissey Chief Financial Officer
-
Susan Patricia Park Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 158,445,435 8.73%
National Nominees Limited 111,876,013 6.17%
J P Morgan Nominees Australia Pty Limited 99,001,452 5.46%
Shenasaby Investments Pty Ltd <The Shenasaby A/C> 73,420,124 4.05%
UBS Nominees Pty Ltd 53,608,927 2.96%
Caperi Pty Ltd <Caperi A/C> 52,573,784 2.90%
Hsbc Custody Nominees (Australia) Limited 47,689,862 2.63%
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 34,339,755 1.89%
BNP Paribas Nominees Pty Ltd<Ib Au Noms Retailclient> 25,783,783 1.42%
Zenith Pacific Limited 22,272,222 1.23%
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 20,067,318 1.11%
Dr Henry William Bosch 18,836,702 1.04%
Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 15,166,667 0.84%
Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 12,378,182 0.68%
Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 10,930,000 0.60%
Mr Vincent Peter Ippolito 10,801,644 0.60%
BNP Paribas Noms Pty Ltd 9,542,034 0.53%
UBS Nominees Pty Ltd i 9,523,810 0.53%
Netwealth Investments Limited <Wrap Services A/C> 8,277,790 0.46%
Mr Nicolas Stephane Fayd'Herbe <Fayd'Herbe Family A/C> 7,888,032 0.43%

Profile

since

Note